SPONSORS & EXHIBITORS

Takis is a biotechnology company specialized in developing breakthrough immunotherapies for infectious disease and oncology fields. Founded in 2009 by a group of scientists from the multinational Merck & Co with over 20 years of experience in gene therapies and immunology, over the years Takis team has provided important direct contributions to the development of new vaccination platforms, including COVID-eVax, a DNA-based vaccine against COVID-19 proven to be safe and immunogenic in a first-in-human phase 1 trial. Recently, a BSL3 facility has been realized to perform in vitro and in vivo research activities with high-risk pathogens, and a GMP laboratory dedicated to clinical grade production of nucleic acids has been implemented. The company is also specialized in the research and development of potential oncological therapies, including cancer genetic vaccines and monoclonal antibodies, particularly humanized monoclonal antibodies designed for oncology and infectious diseases using in vivo electro-gene-transfer technology. Moreover, Takis offers fee-for-service options for preclinical in vitro and in vivo models, monoclonal antibody production, as well as for vaccine development. The company provides custom services for the generation of antibodies against poorly immunogenic antigens and for performing preclinical studies focused on immune-oncology research.

Booth N°7 | http://www.takisbiotech.it